A sweeping overhaul of the CDC’s top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.
A sweeping overhaul of the CDC’s top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.